Literature DB >> 10485469

AF17q25, a putative septin family gene, fuses the MLL gene in acute myeloid leukemia with t(11;17)(q23;q25).

T Taki1, H Ohnishi, K Shinohara, M Sako, F Bessho, M Yanagisawa, Y Hayashi.   

Abstract

The t(11;17) has been described in patients with acute myeloid leukemia (AML), and the AF17 gene was previously cloned as a fusion partner of the MLL gene in t(11;17)(q23;q21)-AML. We analyzed one patient with de novo AML and one with therapy-related AML with t(11;17)(q23;q25) and identified the AF17q25 gene on chromosome 17q25, a putative septin family gene, fused with MLL. AF17q25 encoded at least three kinds of proteins [type I (568 a.a.), type II (594 a.a.), and type III (574 a.a.)] that contained two kinds of different amino acid sequences at the COOH terminus. The MLL-AF17q25 fusion transcript consisted of type I AF17q25 transcript. The AF17q25 protein is homologous to septin family proteins, including H5, NEDD5, CDC10, and hCDCrel, which is one of the fusion partners of MLL in t(11;22)(q23;q11)-AML. These results suggest that AF17q25 and hCDCrel might define a new septin family particularly involved in the pathogenesis of 11q23-associated leukemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485469

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  The septin CDCrel-1 is dispensable for normal development and neurotransmitter release.

Authors:  Xiao-Rong Peng; Zhengping Jia; Yu Zhang; Jerry Ware; William S Trimble
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

2.  The mammalian septin MSF localizes with microtubules and is required for completion of cytokinesis.

Authors:  Mark C Surka; Christopher W Tsang; William S Trimble
Journal:  Mol Biol Cell       Date:  2002-10       Impact factor: 4.138

Review 3.  Conquering the complex world of human septins: implications for health and disease.

Authors:  E A Peterson; E M Petty
Journal:  Clin Genet       Date:  2010-02-11       Impact factor: 4.438

Review 4.  Roles of a trithorax group gene, MLL, in hematopoiesis.

Authors:  Ryoichi Ono; Tetsuya Nosaka; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2005-05       Impact factor: 2.490

5.  An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome.

Authors:  Lisa M Baumann Kreuziger; Julie Cliff Porcher; Rhett P Ketterling; David P Steensma
Journal:  Leuk Res       Date:  2007-01-23       Impact factor: 3.156

6.  Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia.

Authors:  P J Kourlas; M P Strout; B Becknell; M L Veronese; C M Croce; K S Theil; R Krahe; T Ruutu; S Knuutila; C D Bloomfield; M A Caligiuri
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

7.  Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.

Authors:  Ryoichi Ono; Hideaki Nakajima; Katsutoshi Ozaki; Hidetoshi Kumagai; Toshiyuki Kawashima; Tomohiko Taki; Toshio Kitamura; Yasuhide Hayashi; Tetsuya Nosaka
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

8.  Identification of a chromosomal breakpoint and detection of a novel form of an MLL-AF17 fusion transcript in acute monocytic leukemia with t(11;17)(q23;q21).

Authors:  Kazumi Suzukawa; Seiichi Shimizu; Noriko Nemoto; Naoko Takei; Tomohiko Taki; Toshiro Nagasawa
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

9.  Characterization of a SEPT9 interacting protein, SEPT14, a novel testis-specific septin.

Authors:  Esther A Peterson; Linda M Kalikin; Jonathan D Steels; Mathew P Estey; William S Trimble; Elizabeth M Petty
Journal:  Mamm Genome       Date:  2007-10-06       Impact factor: 2.957

10.  Fusion of MLL and MSF in adult de novo acute myelomonocytic leukemia (M4) with t(11;17)(q23;q25).

Authors:  Koh Yamamoto; Fumi Shibata; Mitsuko Yamaguchi; Osamu Miura
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.